Kime C, Mandegar MA, Srivastava D, Yamanaka S, Conklin BR, Rand TA.  2016.  Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells.. Curr Protoc Hum Genet. 88:Unit21.4.
Kime C, Rand TA, Ivey KN, Srivastava D, Yamanaka S, Tomoda K.  2015.  Practical Integration-Free Episomal Methods for Generating Human Induced Pluripotent Stem Cells.. Curr Protoc Hum Genet. 87:21.2.1-21.
Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M et al..  2015.  Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches.. Cell Stem Cell. 16(6):699-711.
Li HLisa, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H et al..  2015.  Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.. Stem Cell Reports. 4(1):143-54.
Kim S-I, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K.  2015.  KLF4 N-terminal variance modulates induced reprogramming to pluripotency.. Stem Cell Reports. 4(4):727-43.
Hayashi Y, Caboni L, Das D, Yumoto F, Clayton T, Deller MC, Nguyen P, Farr CL, Chiu H-J, Miller MD et al..  2015.  Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells.. Proc Natl Acad Sci U S A. 112(15):4666-71.
Sadahiro T, Yamanaka S, Ieda M.  2015.  Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications.. Circ Res. 116(8):1378-91.
Wilmut I, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, Turner D, Turner ML, Yamanaka S, Taylor CJ.  2015.  Development of a global network of induced pluripotent stem cell haplobanks.. Regen Med. 10(3):235-8.
Karagiannis P, Yamanaka S.  2014.  The fate of cell reprogramming.. Nat Methods. 11(10):1006-8.
Andrews PW, Cavanagro J, Deans R, Feigel E, Horowitz E, Keating A, Rao M, Turner M, Wilmut I, Yamanaka S.  2014.  Corrigendum: Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.. Nat Biotechnol. 32(11):1166.
Numasawa-Kuroiwa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Osaka H, Inoue K et al..  2014.  Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes.. Stem Cell Reports. 2(5):648-61.
Bershteyn M, Hayashi Y, Desachy G, Hsiao EC, Sami S, Tsang KM, Weiss LA, Kriegstein AR, Yamanaka S, Wynshaw-Boris A.  2014.  Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells.. Nature. 507(7490):99-103.
Hirata N, Nakagawa M, Fujibayashi Y, Yamauchi K, Murata A, Minami I, Tomioka M, Kondo T, Kuo T-F, Endo H et al..  2014.  A chemical probe that labels human pluripotent stem cells.. Cell Rep. 6(6):1165-74.
Worringer KA, Rand TA, Hayashi Y, Sami S, Takahashi K, Tanabe K, Narita M, Srivastava D, Yamanaka S.  2014.  The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes.. Cell Stem Cell. 14(1):40-52.
Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T et al..  2014.  Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.. Cell. 156(4):663-77.
Ohnuki M, Tanabe K, Sutou K, Teramoto I, Sawamura Y, Narita M, Nakamura M, Tokunaga Y, Nakamura M, Watanabe A et al..  2014.  Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential.. Proc Natl Acad Sci U S A. 111(34):12426-31.
C Spencer I, Baba S, Nakamura K, Hua EA, Sears MAF, Fu C-cheng, Zhang J, Balijepalli S, Tomoda K, Hayashi Y et al..  2014.  Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.. Stem Cell Reports. 3(2):269-81.
Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H et al..  2014.  Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice.. Stem Cell Reports. 3(2):242-9.
Andrews PW, Cavagnaro J, Cavanagro J, Deans R, Feigal E, Feigel E, Horowitz E, Keating A, Rao M, Turner M et al..  2014.  Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.. Nat Biotechnol. 32(8):724-6.
Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita K-ichi, Koike T, Harimoto K-ichi, Dohda T et al..  2014.  Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells.. Cell Stem Cell. 14(4):535-48.
Tokunaga K, Saitoh N, Goldberg IG, Sakamoto C, Yasuda Y, Yoshida Y, Yamanaka S, Nakao M.  2014.  Computational image analysis of colony and nuclear morphology to evaluate human induced pluripotent stem cells.. Sci Rep. 4:6996.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Sasaki A, Yamamoto M, Nakamura M, Sutou K, Osafune K, Yamanaka S.  2014.  Induction of pluripotency in human somatic cells via a transient state resembling primitive streak-like mesendoderm.. Nat Commun. 5:3678.
Tamaoki N, Takahashi K, Aoki H, Iida K, Kawaguchi T, Hatakeyama D, Inden M, Chosa N, Ishisaki A, Kunisada T et al..  2014.  The homeobox gene DLX4 promotes generation of human induced pluripotent stem cells.. Sci Rep. 4:7283.
Tanabe K, Takahashi K, Yamanaka S.  2014.  Induction of pluripotency by defined factors.. Proc Jpn Acad Ser B Phys Biol Sci. 90(3):83-96.
Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M et al..  2014.  A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.. Sci Rep. 4:3594.
Shimamoto R, Amano N, Ichisaka T, Watanabe A, Yamanaka S, Okita K.  2014.  Generation and characterization of induced pluripotent stem cells from Aid-deficient mice.. PLoS One. 9(4):e94735.
Pandey RRaman, Tokuzawa Y, Yang Z, Hayashi E, Ichisaka T, Kajita S, Asano Y, Kunieda T, Sachidanandam R, Chuma S et al..  2013.  Tudor domain containing 12 (TDRD12) is essential for secondary PIWI interacting RNA biogenesis in mice.. Proc Natl Acad Sci U S A. 110(41):16492-7.
Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A, Turner D, Yamanaka S, Wilmut I.  2013.  Toward the development of a global induced pluripotent stem cell library.. Cell Stem Cell. 13(4):382-4.
Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, Yamanaka S.  2013.  An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells.. Stem Cells. 31(3):458-66.
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I et al..  2013.  Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".. Sci Transl Med. 5(188):188lr2.
Veraitch O, Kobayashi T, Imaizumi Y, Akamatsu W, Sasaki T, Yamanaka S, Amagai M, Okano H, Ohyama M.  2013.  Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo.. J Invest Dermatol. 133(6):1479-88.
Takahashi K, Yamanaka S.  2013.  Induced pluripotent stem cells in medicine and biology.. Development. 140(12):2457-61.
Tanabe K, Nakamura M, Narita M, Takahashi K, Yamanaka S.  2013.  Maturation, not initiation, is the major roadblock during reprogramming toward pluripotency from human fibroblasts.. Proc Natl Acad Sci U S A. 110(30):12172-9.
Watanabe A, Yamada Y, Yamanaka S.  2013.  Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier.. Philos Trans R Soc Lond B Biol Sci. 368(1609):20120292.
Yamana R, Iwasaki M, Wakabayashi M, Nakagawa M, Yamanaka S, Ishihama Y.  2013.  Rapid and deep profiling of human induced pluripotent stem cell proteome by one-shot NanoLC-MS/MS analysis with meter-scale monolithic silica columns.. J Proteome Res. 12(1):214-21.
Yamanaka S.  2013.  Shinya Yamanaka: purveyor of pluripotency. Interview by Ruth Williams.. Circ Res. 112(2):233-5.
Fujishiro S-hei, Nakano K, Mizukami Y, Azami T, Arai Y, Matsunari H, Ishino R, Nishimura T, Watanabe M, Abe T et al..  2013.  Generation of naive-like porcine-induced pluripotent stem cells capable of contributing to embryonic and fetal development.. Stem Cells Dev. 22(3):473-82.
Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S, Miura K.  2013.  Steps toward safe cell therapy using induced pluripotent stem cells.. Circ Res. 112(3):523-33.
Payer B, Rosenberg M, Yamaji M, Yabuta Y, Koyanagi-Aoi M, Hayashi K, Yamanaka S, Saitou M, Lee JT.  2013.  Tsix RNA and the germline factor, PRDM14, link X reactivation and stem cell reprogramming.. Mol Cell. 52(6):805-18.
Yamanaka S.  2013.  The winding road to pluripotency (Nobel Lecture).. Angew Chem Int Ed Engl. 52(52):13900-9.
Koyanagi-Aoi M, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, Teramoto I, Narita M, Sato Y, Ichisaka T et al..  2013.  Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells.. Proc Natl Acad Sci U S A. 110(51):20569-74.
Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K et al..  2013.  Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.. Cell Stem Cell. 12(4):487-96.
Kaneko S, Yamanaka S.  2013.  To be immunogenic, or not to be: that's the iPSC question.. Cell Stem Cell. 12(4):385-6.
Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE.  2013.  Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.. Sci Rep. 3:1978.
Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S et al..  2013.  Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate.. Stem Cell Reports. 1(4):283-92.
Matsumoto Y, Hayashi Y, Schlieve CR, Ikeya M, Kim H, Nguyen TD, Sami S, Baba S, Barruet E, Nasu A et al..  2013.  Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation.. Orphanet J Rare Dis. 8:190.
Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J, Hattori T, Ohno S, Kita T, Horie M et al..  2013.  Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture.. Circ J. 77(5):1307-14.
Mae S-I, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K et al..  2013.  Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.. Nat Commun. 4:1367.
Miki K, Uenaka H, Saito A, Miyagawa S, Sakaguchi T, Higuchi T, Shimizu T, Okano T, Yamanaka S, Sawa Y.  2012.  Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats.. Stem Cells Transl Med. 1(5):430-7.
Lahti AL, Kujala VJ, Chapman H, Koivisto A-P, Pekkanen-Mattila M, Kerkelä E, Hyttinen J, Kontula K, Swan H, Conklin BR et al..  2012.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.. Dis Model Mech. 5(2):220-30.
Yamanaka S.  2012.  Induced pluripotent stem cells: past, present, and future.. Cell Stem Cell. 10(6):678-84.
Hayashi Y, Saitou M, Yamanaka S.  2012.  Germline development from human pluripotent stem cells toward disease modeling of infertility.. Fertil Steril. 97(6):1250-9.
Kajiwara M, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, Endo H, Eto K, Toguchida J, Uemoto S et al..  2012.  Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells.. Proc Natl Acad Sci U S A. 109(31):12538-43.
Tomoda K, Takahashi K, Leung K, Okada A, Narita M, N Yamada A, Eilertson KE, Tsang P, Baba S, White MP et al..  2012.  Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.. Cell Stem Cell. 11(1):91-9.
Blanpain C, Daley GQ, Hochedlinger K, Passegué E, Rossant J, Yamanaka S.  2012.  Stem cells assessed.. Nat Rev Mol Cell Biol. 13(7):471-6.
Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, Niwa A, Nishikomori R, Kambe N, Hara H et al..  2012.  Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery.. Blood. 120(6):1299-308.
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I et al..  2012.  Drug screening for ALS using patient-specific induced pluripotent stem cells.. Sci Transl Med. 4(145):145ra104.
Kobayashi Y, Okada Y, Itakura G, Iwai H, Nishimura S, Yasuda A, Nori S, Hikishima K, Konomi T, Fujiyoshi K et al..  2012.  Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity.. PLoS One. 7(12):e52787.
Okita K, Nagata N, Yamanaka S.  2011.  Immunogenicity of induced pluripotent stem cells.. Circ Res. 109(7):720-1.
Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, Fujiyoshi K, Koike M, Uchiyama Y, Ikeda E et al..  2011.  Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice.. Proc Natl Acad Sci U S A. 108(40):16825-30.
Nakamura T, Nakagawa M, Ichisaka T, Shiota A, Yamanaka S.  2011.  Essential roles of ECAT15-2/Dppa2 in functional lung development.. Mol Cell Biol. 31(21):4366-78.
Wang Y-C, Nakagawa M, Garitaonandia I, Slavin I, Altun G, Lacharite RM, Nazor KL, Tran HT, Lynch CL, Leonardo TR et al..  2011.  Specific lectin biomarkers for isolation of human pluripotent stem cells identified through array-based glycomic analysis.. Cell Res. 21(11):1551-63.
Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K-I et al..  2011.  A more efficient method to generate integration-free human iPS cells.. Nat Methods. 8(5):409-12.
Maekawa M, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, Ichisaka T, Kawamura Y, Mochizuki H, Goshima N, Yamanaka S.  2011.  Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1.. Nature. 474(7350):225-9.
Higashi H, Brüstle O, Daley GQ, Yamanaka S.  2011.  The nomenclature system should be sustainable, but also practical.. Cell Stem Cell. 8(6):606-7.
Yoshida Y, Yamanaka S.  2011.  iPS cells: a source of cardiac regeneration.. J Mol Cell Cardiol. 50(2):327-32.
Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N.  2011.  Modeling familial Alzheimer's disease with induced pluripotent stem cells.. Hum Mol Genet. 20(23):4530-9.
Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S et al..  2011.  Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.. Nat Biotechnol. 29(12):1132-44.
Sakurai H, Yamanaka S.  2011.  [Research for cell therapy by induced pluripotent stem cell].. Nihon Rinsho. 69(12):2114-8.
Okita K, Yamanaka S.  2011.  Induced pluripotent stem cells: opportunities and challenges.. Philos Trans R Soc Lond B Biol Sci. 366(1575):2198-207.
Fujiwara M, Yan P, Otsuji TG, Narazaki G, Uosaki H, Fukushima H, Kuwahara K, Harada M, Matsuda H, Matsuoka S et al..  2011.  Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A.. PLoS One. 6(2):e16734.
Yahata N, Asai M, Kitaoka S, Takahashi K, Asaka I, Hioki H, Kaneko T, Maruyama K, Saido TC, Nakahata T et al..  2011.  Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease.. PLoS One. 6(9):e25788.
Hiratsuka M, Uno N, Ueda K, Kurosaki H, Imaoka N, Kazuki K, Ueno E, Akakura Y, Katoh M, Osaki M et al..  2011.  Integration-free iPS cells engineered using human artificial chromosome vectors.. PLoS One. 6(10):e25961.
Iwabuchi KA, Yamakawa T, Sato Y, Ichisaka T, Takahashi K, Okita K, Yamanaka S.  2011.  ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency.. PLoS One. 6(5):e20461.
Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H et al..  2011.  Generation of human melanocytes from induced pluripotent stem cells.. PLoS One. 6(1):e16182.
Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, Yamashita JK.  2011.  Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression.. PLoS One. 6(8):e23657.
Homma K, Sone M, Taura D, Yamahara K, Suzuki Y, Takahashi K, Sonoyama T, Inuzuka M, Fukunaga Y, Tamura N et al..  2010.  Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells.. Atherosclerosis. 212(1):42-7.
Espejel S, Roll GR, K McLaughlin J, Lee AY, Zhang JY, Laird DJ, Okita K, Yamanaka S, Willenbring H.  2010.  Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.. J Clin Invest. 120(9):3120-6.
Imamura M, Aoi T, Tokumasu A, Mise N, Abe K, Yamanaka S, Noce T.  2010.  Induction of primordial germ cells from mouse induced pluripotent stem cells derived from adult hepatocytes.. Mol Reprod Dev. 77(9):802-11.
Okita K, Yamanaka S.  2010.  Induction of pluripotency by defined factors.. Exp Cell Res. 316(16):2565-70.
Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, Morimoto T, Ono K, Baba S, Doi H et al..  2010.  Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice.. Cardiovasc Res. 88(2):314-23.
Nakahata T, Awaya T, Chang H, Mizuno Y, Niwa A, Fukada S-ichiro, Takeda S'ichi, Yamanaka S, Heike T.  2010.  Derivation of engraftable myogenic precursors from murine ES/iPS cells and generation of disease-specific iPS cells from patients with Duchenne muscular dystrophy (DMD) and other diseases.. Rinsho Shinkeigaku. 50(11):889.
Okita K, Hong H, Takahashi K, Yamanaka S.  2010.  Generation of mouse-induced pluripotent stem cells with plasmid vectors.. Nat Protoc. 5(3):418-28.
Yamanaka S, Blau HM.  2010.  Nuclear reprogramming to a pluripotent state by three approaches.. Nature. 465(7299):704-12.
Yamanaka S.  2010.  An interview with... Shinya Yamanaka. Interview by Mary Muers.. Nat Rev Genet. 11(6):390.
Sato S, Yagi S, Arai Y, Hirabayashi K, Hattori N, Iwatani M, Okita K, Ohgane J, Tanaka S, Wakayama T et al..  2010.  Genome-wide DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) residing in mouse pluripotent stem cells.. Genes Cells. 15(6):607-18.
Yamanaka S.  2010.  Patient-specific pluripotent stem cells become even more accessible.. Cell Stem Cell. 7(1):1-2.
Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S et al..  2010.  Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury.. Proc Natl Acad Sci U S A. 107(28):12704-9.
Mizuno Y, Chang H, Umeda K, Niwa A, Iwasa T, Awaya T, Fukada S-ichiro, Yamamoto H, Yamanaka S, Nakahata T et al..  2010.  Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells.. FASEB J. 24(7):2245-53.
Saunders LR, Sharma ADeep, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H, Verdin E.  2010.  miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues.. Aging (Albany NY). 2(7):415-31.
Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K, Yoshino T, Kazuki K, Ishihara C et al..  2010.  Complete genetic correction of ips cells from Duchenne muscular dystrophy.. Mol Ther. 18(2):386-93.
Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M et al..  2010.  Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells.. J Exp Med. 207(13):2817-30.
Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S.  2010.  Promotion of direct reprogramming by transformation-deficient Myc.. Proc Natl Acad Sci U S A. 107(32):14152-7.
Egusa H, Okita K, Kayashima H, Yu G, Fukuyasu S, Saeki M, Matsumoto T, Yamanaka S, Yatani H.  2010.  Gingival fibroblasts as a promising source of induced pluripotent stem cells.. PLoS One. 5(9):e12743.
Nakagawa M, Yamanaka S.  2010.  Reprogramming of somatic cells to pluripotency.. Adv Exp Med Biol. 695:215-24.
Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S.  2009.  Hypoxia enhances the generation of induced pluripotent stem cells.. Cell Stem Cell. 5(3):237-41.
Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T.  2009.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.. Biochem Biophys Res Commun. 387(3):482-8.
Nishimura K, Nakagawa T, Ono K, Ogita H, Sakamoto T, Yamamoto N, Okita K, Yamanaka S, Ito J.  2009.  Transplantation of mouse induced pluripotent stem cells into the cochlea.. Neuroreport. 20(14):1250-4.
Yamanaka S.  2009.  Ekiden to iPS Cells.. Nat Med. 15(10):1145-8.
Niwa A, Umeda K, Chang H, Saito M, Okita K, Takahashi K, Nakagawa M, Yamanaka S, Nakahata T, Heike T.  2009.  Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors.. J Cell Physiol. 221(2):367-77.
Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, Okita K, Yamanaka S, Nishimura Y.  2009.  Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells.. Stem Cells. 27(5):1021-31.
Daley GQ, M Lensch W, Jaenisch R, Meissner A, Plath K, Yamanaka S.  2009.  Broader implications of defining standards for the pluripotency of iPSCs.. Cell Stem Cell. 4(3):200-1;authorreply202.
Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, Takahashi K, Homma K, Oyamada N, Inuzuka M et al..  2009.  Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells.. FEBS Lett. 583(6):1029-33.
Ohnuki M, Takahashi K, Yamanaka S.  2009.  Generation and characterization of human induced pluripotent stem cells.. Curr Protoc Stem Cell Biol. Chapter 4:Unit4A.2.
Tsubooka N, Ichisaka T, Okita K, Takahashi K, Nakagawa M, Yamanaka S.  2009.  Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts.. Genes Cells. 14(6):683-94.
Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, Yoshimura N, Takahashi M.  2009.  Generation of retinal cells from mouse and human induced pluripotent stem cells.. Neurosci Lett. 458(3):126-31.
Yamanaka S.  2009.  Elite and stochastic models for induced pluripotent stem cell generation.. Nature. 460(7251):49-52.
Taura D, Sone M, Homma K, Oyamada N, Takahashi K, Tamura N, Yamanaka S, Nakao K.  2009.  Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report.. Arterioscler Thromb Vasc Biol. 29(7):1100-3.
Aiba K, Nedorezov T, Piao Y, Nishiyama A, Matoba R, Sharova LV, Sharov AA, Yamanaka S, Niwa H, Ko MSH.  2009.  Defining developmental potency and cell lineage trajectories by expression profiling of differentiating mouse embryonic stem cells.. DNA Res. 16(1):73-80.
Nagata S, Toyoda M, Yamaguchi S, Hirano K, Makino H, Nishino K, Miyagawa Y, Okita H, Kiyokawa N, Nakagawa M et al..  2009.  Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells.. Genes Cells. 14(12):1395-404.
Belmonte JCarlos Izp, Ellis J, Hochedlinger K, Yamanaka S.  2009.  Induced pluripotent stem cells and reprogramming: seeing the science through the hype.. Nat Rev Genet. 10(12):878-83.
Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H, Hattori F, Egashira T, Seki T, Ohno Y et al..  2009.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes.. Biochem Biophys Res Commun. 385(4):497-502.
Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S.  2009.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.. Nature. 460(7259):1132-5.
Silva J, Nichols J, Theunissen TW, Guo G, van Oosten AL, Barrandon O, Wray J, Yamanaka S, Chambers I, Smith A.  2009.  Nanog is the gateway to the pluripotent ground state.. Cell. 138(4):722-37.
Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M et al..  2009.  Variation in the safety of induced pluripotent stem cell lines.. Nat Biotechnol. 27(8):743-5.
Yamanaka S.  2009.  A fresh look at iPS cells.. Cell. 137(1):13-7.
Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S.  2009.  Human induced pluripotent stem cells on autologous feeders.. PLoS One. 4(12):e8067.
Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu S-I, Kondo Y et al..  2009.  ERas is expressed in primate embryonic stem cells but not related to tumorigenesis.. Cell Transplant. 18(4):381-9.
Nakamura K, Salomonis N, Tomoda K, Yamanaka S, Conklin BR.  2009.  G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies.. PLoS One. 4(11):e7780.
Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S.  2008.  Generation of mouse induced pluripotent stem cells without viral vectors.. Science. 322(5903):949-53.
Yamanaka S.  2008.  Pluripotency and nuclear reprogramming.. Philos Trans R Soc Lond B Biol Sci. 363(1500):2079-87.
Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK.  2008.  Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells.. Circulation. 118(5):498-506.
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S.  2008.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.. Nat Biotechnol. 26(1):101-6.
Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S.  2008.  Generation of pluripotent stem cells from adult mouse liver and stomach cells.. Science. 321(5889):699-702.
Hyun I, Hochedlinger K, Jaenisch R, Yamanaka S.  2007.  New advances in iPS cell research do not obviate the need for human embryonic stem cells.. Cell Stem Cell. 1(4):367-8.
Lewitzky M, Yamanaka S.  2007.  Reprogramming somatic cells towards pluripotency by defined factors.. Curr Opin Biotechnol. 18(5):467-73.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S.  2007.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.. Cell. 131(5):861-72.
Okita K, Ichisaka T, Yamanaka S.  2007.  Generation of germline-competent induced pluripotent stem cells.. Nature. 448(7151):313-7.
Takahashi K, Okita K, Nakagawa M, Yamanaka S.  2007.  Induction of pluripotent stem cells from fibroblast cultures.. Nat Protoc. 2(12):3081-9.
Okita K, Yamanaka S.  2006.  Intracellular signaling pathways regulating pluripotency of embryonic stem cells.. Curr Stem Cell Res Ther. 1(1):103-11.
Yamanaka S.  2006.  [Molecular mechanisms underlying pluripotency of embryonic stem cells].. Seikagaku. 78(1):27-33.
Yamanaka S, Takahashi K.  2006.  [Induction of pluripotent stem cells from mouse fibroblast cultures].. Tanpakushitsu Kakusan Koso. 51(15):2346-51.
Tanaka TS, de Silanes ILopez, Sharova LV, Akutsu H, Yoshikawa T, Amano H, Yamanaka S, Gorospe M, Ko MSH.  2006.  Esg1, expressed exclusively in preimplantation embryos, germline, and embryonic stem cells, is a putative RNA-binding protein with broad RNA targets.. Dev Growth Differ. 48(6):381-90.
Amano H, Itakura K, Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S.  2006.  Identification and targeted disruption of the mouse gene encoding ESG1 (PH34/ECAT2/DPPA5).. BMC Dev Biol. 6:11.
Imamura M, Miura K, Iwabuchi K, Ichisaka T, Nakagawa M, Lee J, Kanatsu-Shinohara M, Shinohara T, Yamanaka S.  2006.  Transcriptional repression and DNA hypermethylation of a small set of ES cell marker genes in male germline stem cells.. BMC Dev Biol. 6:34.
Tokuzawa Y, Maruyama M, Yamanaka S.  2006.  Utilization of digital differential display to identify novel targets of Oct3/4.. Methods Mol Biol. 329:223-31.
Takahashi K, Ichisaka T, Yamanaka S.  2006.  Identification of genes involved in tumor-like properties of embryonic stem cells.. Methods Mol Biol. 329:449-58.
Takahashi K, Nakagawa M, Young SG, Yamanaka S.  2005.  Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway.. J Biol Chem. 280(38):32768-74.
Nakagawa M, Yamanaka S.  2005.  [Mechanism for maintaining pluripotency in embryonic stem cells and inner cell mass].. Tanpakushitsu Kakusan Koso. 50(6 Suppl):546-50.
Takahashi K, Maruyama M, Tokuzawa Y, Murakami M, Oda Y, Yoshikane N, Makabe KW, Ichisaka T, Yamanaka S.  2005.  Evolutionarily conserved non-AUG translation initiation in NAT1/p97/DAP5 (EIF4G2).. Genomics. 85(3):360-71.
Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S.  2005.  Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells.. J Biol Chem. 280(26):24371-9.
Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato J-Y.  2004.  Multiple functions of Jab1 are required for early embryonic development and growth potential in mice.. J Biol Chem. 279(41):43013-8.
Matsuda E, Shigeoka T, Iida R, Yamanaka S, Kawaichi M, Ishida Y.  2004.  Expression profiling with arrays of randomly disrupted genes in mouse embryonic stem cells leads to in vivo functional analysis.. Proc Natl Acad Sci U S A. 101(12):4170-4.
Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S.  2003.  The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells.. Cell. 113(5):631-42.
Takahashi K, Mitsui K, Yamanaka S.  2003.  Role of ERas in promoting tumour-like properties in mouse embryonic stem cells.. Nature. 423(6939):541-5.
Tokuzawa Y, Kaiho E, Maruyama M, Takahashi K, Mitsui K, Maeda M, Niwa H, Yamanaka S.  2003.  Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development.. Mol Cell Biol. 23(8):2699-708.